Reactivation of p53 as therapeutic intervention for malignant melanoma

Current Opinion in Oncology

Volumn 26, Issue 1, 2014, Pages 114-119

  Jochemsen, Aart G ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Mdmx melanoma; p53; p63; p73

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; APOPTOSIS STIMULATING PROTEIN OF P53; APR 246; B RAF KINASE; B RAF KINASE INHIBITOR; CISPLATIN; CYCLIN DEPENDENT KINASE 1 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; DNA; MELPHALAN; MESSENGER RNA; MI 63; NUTLIN 3; PRIMA; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P27; PROTEIN P53; PROTEIN P63; PROTEIN P73; RITA; RO 5963; UNCLASSIFIED DRUG; VEMURAFENIB;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATTENUATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CUTANEOUS MELANOMA; DNA DAMAGE; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MELANOMA; MELANOMA CELL; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TREATMENT DURATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UVEA MELANOMA; WILD TYPE;

ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84890556331     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000033     Document Type: Review

References (49)

1. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46:270-283.
2. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44:1345-1389.
3. Melanoma of the skin, cancer fact sheets, NCI. Seer Database 2007.
4. Cancer epidemiology in older adolescents & young adults. Seer AYA Monograph 2007; 53-57.
5. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220-241.
6. Pretto F, Neri D. Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure. Pharmacol Ther 2013; 139:405-411.
7. Solus JF, Kraft S. Ras, Raf, and MAP kinase in melanoma. Adv Anat Pathol 2013; 20:217-226. Comprehensive review on the role of the RAS-RAF-MAPK pathway in melanoma.
8. Salama AK, Flaherty KT. BRAF in melanoma: Current strategies and future directions. Clin Cancer Res 2013; 19:4326-4334. Timely review on the function and targeting of mutant BRAF in melanoma.
9. Carlino MS, Gowrishankar K, Saunders CA, et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway Inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013; 12:1342.
10. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012; 18:142-147.
11. Schlegel J, Sambade MJ, Sather S, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013; 123:2257-2267.
12. Tworkoski KA, Platt JT, Bacchiocchi A, et al. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res 2013; 26:527-541.
13. Griewank KG, Ugurel S, Schadendorf D, Paschen A. New developments in biomarkers for melanoma. Curr Opin Oncol 2013; 25:145-151.
14. Griewank KG, Murali R. Pathology and genetics of uveal melanoma. Pathology 2013; 45:18-27.
15. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
16. Hainaut P, Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000; 77:81-137.
17. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2:a001008.
18. Chin L, Garraway LA, Fisher DE. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-2182.
19. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-263. In this study, the analysis of large-scale melanoma exome data led to the discovery of six novel melanoma genes, some of which harbored recurrent and potentially targetable mutations. In addition, a basis for pRB and p53 pathway deregulation in melanoma is presented.
20. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83-96. Timely, comprehensive review on the role of high Mdm2/Mdmx in oncogenesis and the possibilities to reactivate p53 as cancer therapy.
21. Muthusamy V, Hobbs C, Nogueira C, et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006; 45:447-454.
22. Gembarska A, Luciani F, Fedele C, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012; 18:1239-1247. In this study, the high expression of Mdmx in a large proportion of fresh melanoma samples and early passage cell lines is shown. Furthermore, the importance of Mdmx expression for the proliferation and survival of melanoma cells is revealed.
23. de Lange J, Teunisse AF, Verlaan-de Vries M, et al. High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res 2012; 2:492-507.
24. Bernal F, Wade M, Godes M, et al. A stapled p53 helix overcomes HDMXmediated suppression of p53. Cancer Cell 2010; 18:411-422.
25. Brown CJ, Quah ST, Jong J, et al. Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 2013; 8:506-512.
26. Graves B, Thompson T, Xia M, et al. Activation of the p53 pathway by smallmolecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 2012; 109:11788-11793. This publication presents the first dual Mdmx/Mdm2 inhibitor, which activates p53 in high Mdmx-expressing tumor cells.
27. Michaelis M, Rothweiler F, Barth S, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multidrug-resistant cancer cells. Cell Death Dis 2011; 2:e243.
28. Jones RJ, Bjorklund CC, Baladandayuthapani V, et al. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 2012; 11:2243-2253.
29. Zhao CY, Grinkevich VV, Nikulenkov F, et al. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9:1847-1855.
30. de Lange J, Ly LV, Lodder K, et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 2012; 31:1105-1116. This publication shows the synergism between the different class p53 activators Nutlin-3 and RITA in the killing of melanoma cells.
31. Michaelis M, Rothweiler F, Agha B, et al. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis 2012; 3:e294.
32. Spinnler C, Hedstrom E, Li H, et al. Abrogation of Wip1 expression by RITAactivated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ 2011; 18:1736-1745.
33. de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG. Chk2 mediates RITA-induced apoptosis. Cell Death Differ 2012; 19:980-989.
34. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15:376-388.
35. Lambert JM, Moshfegh A, Hainaut P, et al. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010; 29:1329-1338.
36. Bao W, Chen M, Zhao X, et al. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 2011; 10:301-307.
37. Sullivan A, Lu X. ASPP: A new family of oncogenes and tumour suppressor genes. Br J Cancer 2007; 96:196-200.
38. Lu M., Breyssens H., Salter V., et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013; 23: 618-633.
39. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321-1328.
40. Bell HS, Dufes C, O'Prey J, et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007; 117:1008-1018.
41. Rudolf E, Rudolf K, Cervinka M. Camptothecin induces p53-dependent and-independent apoptogenic signaling in melanoma cells. Apoptosis 2011; 16:1165-1176.
42. Emmrich S, Wang W, John K, et al. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 2009; 8:61.
43. Rufini A, Agostini M, Grespi F, et al. p73 in Cancer. Genes Cancer 2011; 2:491-502.
44. Bailey SG, Cragg MS, Townsend PA. Family friction as DeltaNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011; 43:482-486.
45. Sakiz D, Turkmenoglu TT, Kabukcuoglu F. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract 2009; 205:589-594.
46. Jo VY, Fletcher CD. p63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol 2011; 136:762-766.
47. Matin RN, Chikh A, Chong SL, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med 2013; 210:581-603. This study shows the frequent expression of p63 isoforms in melanoma, which interacts with p53, and thereby prevents its activation upon DNA damage. In that way, p63 expression confers chemoresistance to melanoma cells.
48. Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A 2008; 105:6302-6307.
49. Bernal F, Tyler AF, Korsmeyer SJ, et al. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129:2456-2457.